Increasing the uptake in a general practice prostate cancer screening programme

BMJ Open Quality

article

Neil Limaye¹  Daniele Zorzato¹  Aaruran Nadarajasundaram¹  Sabrina B Y Ong² 

[1] GKT School of Medical Education , King's College London Faculty of Life Sciences and Medicine;NHS Greenwich CCG

关键词: general practice;    continuous quality improvement;    patient education;    health equity;    PDSA;   

DOI  :  10.1136/bmjoq-2021-001701

学科分类：药学

来源: BMJ Publishing Group

【 摘 要 】

Background Prostate cancer (PC) is the second most common cause of cancer deaths among males worldwide. Prostate-specific antigen (PSA) is a predictive indicator of prostate pathology. Men with elevated PSA levels are at increased risk of developing PC. There is currently no UK national PC screening programme, therefore patients often present to general practices (GPs) at later stages of pathology, worsening patient prognosis and outcomes.Local problem The location of the GP surgery had a large patient population at increased risk of PC, namely Afro-Caribbean/Asian males.Methods We conducted baseline measurements to identify male patients over the age of 65 and/or male patients who were at high risk of developing PC. These included previous referred patients or patients with a PSA over 10.0. We then implemented three plan-do-study-act (PDSA) cycles and measured their effect after 2 weeks of starting the respective intervention.Interventions PDSA1: Generating a list of target patients who have not had repeat/follow-up/referral and directly contacting by telephone to invite them for a blood test.PDSA2: Creating patient-specific electronic pop-up reminders on the electronic-patient-record system for PSA follow-up/referral/repeat test.Planned PDSA3: Patient education of prostate health and general self-checking, as well as benefits/risks of undergoing PSA screening in the form of patient focus groups and informative leaflets.Results We identified 220 male patients over 65 registered at a large South London GP surgery. 77.7% of eligible patients had a PSA measurement since 1 April 2019. Our results showed an overall increase in screening of 13.5% from baseline.Conclusions Our project identified patients that may potentially have undiagnosed prostate pathology. However, a key factor for not reaching our goal was blood test refusal. This was further exacerbated by the COVID-19 pandemic, impacting the capacity to disseminate appropriate information to the local population on the importance of PSA screening.

【 授权许可】

CC BY-NC|CC BY|CC BY-NC-ND